Paper · 33358151

Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.

Zoumpourlis P and 3 others. Clin Genitourin Cancer, 2021. Cited by 50 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. Papers, record 33358151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33358151

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.; PubMed
Journal: Clin Genitourin Cancer; PubMed
Year: 2021; PubMed
Publication types: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/33358151/; PubMed
DOI: https://doi.org/10.1016/j.clgc.2020.11.005; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC8169717/; PubMed
The journal: https://conductscience.org/library/journal-index/101260955; PubMed
Citations, by iCite: 50; iCite
Relative citation ratio, by iCite: 2.46; iCite
Revised in PubMed: 2024-08-11; PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Zoumpourlis P	Panagiotis
2	Genovese G	Giannicola
3	Tannir NM	Nizar M
4	Msaouel P	Pavlos

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Carcinoma, Renal Cell	Major topic
Kidney Neoplasms	Major topic
Humans
Prospective Studies
Retrospective Studies

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by
P30 CA016672	NCI NIH HHS	United States	P30CA016672	PubMed and NIH

Source NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References122

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	28,673,798	Rapid Response to Nivolumab in a Patient With Sarcomatoid Transformation of Chromophobe Renal Cell Carcinoma.	Clin Genitourin Cancer	2017	https://conductscience.org/library/papers/28673798	PubMed
2	35,172,487	Metabolic Derangements in Succinate Dehydrogenase B-Mutated Renal-Cell Carcinomas: More Than Meets the Eye?	JCO Precis Oncol	2017	https://conductscience.org/library/papers/35172487	PubMed
3	29,903,415	A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus.	Clin Genitourin Cancer	2018	https://conductscience.org/library/papers/29903415	PubMed
4	22,498,819	TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients.	Am J Surg Pathol	2012	https://conductscience.org/library/papers/22498819	PubMed
5	32,873,572	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.	Clin Cancer Res	2021	https://conductscience.org/library/papers/32873572	PubMed
6	32,800,717	Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.	Clin Genitourin Cancer	2020	https://conductscience.org/library/papers/32800717	PubMed
7	32,469,384	Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.	JAMA Oncol	2020	https://conductscience.org/library/papers/32469384	PubMed
8	26,406,148	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.	N Engl J Med	2015	https://conductscience.org/library/papers/26406148	PubMed
9	26,626,617	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.	Eur Urol	2016	https://conductscience.org/library/papers/26626617	PubMed
10	25,137,021	Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery.	Br J Cancer	2014	https://conductscience.org/library/papers/25137021	PubMed

1 to 10 of 122

See all 122 references

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.

PMID	Title	Journal	Year	In Papers	Source
42,914,499	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma.	ESMO Open	2026	https://conductscience.org/library/papers/42914499	PubMed
42,731,937	Advancing clinical trials for rare renal cell carcinoma subtypes: Consensus statements from the International Kidney Cancer Symposium North America 2025 think tank.	Urol Oncol	2026	https://conductscience.org/library/papers/42731937	PubMed
42,317,258	Lineage infidelity in FH-deficient RCC with secondary somatic alterations: a case report and implications for diagnosis and treatment.	Ther Adv Med Oncol	2026	https://conductscience.org/library/papers/42317258	PubMed
42,122,251	Kidney Cancer Trends, Risk Factors, and Interventions in American Indian and Alaska Native Populations: The Kidney Cancer Association Scientific Statement.	Cancers (Basel)	2026	https://conductscience.org/library/papers/42122251	PubMed
41,294,834	Recent Advances in nccRCC Classification and Therapeutic Approaches.	Cells	2025	https://conductscience.org/library/papers/41294834	PubMed
41,290,625	Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.	Nat Commun	2025	https://conductscience.org/library/papers/41290625	PubMed
40,601,845	Differential Efficacy of Bevacizumab and Erlotinib in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma.	Mol Cancer Ther	2025	https://conductscience.org/library/papers/40601845	PubMed
40,335,555	Comparative analysis of oncologic outcomes in surgically treated patients with renal cell carcinoma and renal vein thrombosis by pathologic subtypes.	Sci Rep	2025	https://conductscience.org/library/papers/40335555	PubMed
40,034,897	A case of papillary renal cell carcinoma with para-aortic lymph node metastasis that was completely resectable after treatment with combination therapy comprising lenvatinib and pembrolizumab and robot-assisted radical nephrectomy.	IJU Case Rep	2025	https://conductscience.org/library/papers/40034897	PubMed
40,008,409	STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma.	Future Oncol	2025	https://conductscience.org/library/papers/40008409	PubMed

1 to 10 of 38

See all 38 cited by

Genes53

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
AKT1	207	PubTator's text mining	https://conductscience.org/library/genes/207	NCBI Gene
ALK	238	PubTator's text mining	https://conductscience.org/library/genes/238	NCBI Gene
ASPSCR1	79,058	PubTator's text mining	https://conductscience.org/library/genes/79058	NCBI Gene
AXL	558	PubTator's text mining	https://conductscience.org/library/genes/558	NCBI Gene
BAP1	8,314	PubTator's text mining	https://conductscience.org/library/genes/8314	NCBI Gene
CD274	29,126	PubTator's text mining	https://conductscience.org/library/genes/29126	NCBI Gene
CDKN2A	1,029	PubTator's text mining	https://conductscience.org/library/genes/1029	NCBI Gene
CDKN2B	1,030	PubTator's text mining	https://conductscience.org/library/genes/1030	NCBI Gene
CGAS	115,004	PubTator's text mining	https://conductscience.org/library/genes/115004	NCBI Gene
CTLA4	1,493	PubTator's text mining	https://conductscience.org/library/genes/1493	NCBI Gene

1 to 10 of 53

See all 53 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33358151

GET https://conductscience.org/api/papers/v1/33358151/references?page=2

API reference For AI assistants